Differential effects of candesartan and olmesartan on adipose tissue activity biomarkers in type II diabetic hypertensive patients

Hypertension Research

Volumn 33, Issue 8, 2010, Pages 790-795

  Derosa, Giuseppe ^a   Maffioli, Pamela ^a   Salvadeo, Sibilla A T ^a   Ferrari, Ilaria ^a   Gravina, Alessia ^a   Mereu, Roberto ^a   Palumbo, Ilaria ^a   Fogari, Elena ^a   D'Angelo, Angela ^a   Cicero, Arrigo F G ^b  

^a UNIVERSITY OF PAVIA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

adipokines; candesartan; olmesartan; type II diabetes mellitus

Indexed keywords

ADIPONECTIN; C REACTIVE PROTEIN; CANDESARTAN; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; OLMESARTAN; PLACEBO; RESISTIN; RETINOL BINDING PROTEIN 4;

ADIPOSE TISSUE; ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; BODY MASS; BODY WEIGHT; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC HYPERTENSION; DIASTOLIC BLOOD PRESSURE; DIET RESTRICTION; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFECT; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATION; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION;

ADIPOSE TISSUE; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BENZIMIDAZOLES; BIOLOGICAL MARKERS; BLOOD PRESSURE; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; FEMALE; GLYCEMIC INDEX; HUMANS; HYPERTENSION; HYPOGLYCEMIC AGENTS; IMIDAZOLES; INSULIN RESISTANCE; MALE; MIDDLE AGED; TETRAZOLES;

EID: 77955369876     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2010.85     Document Type: Article

References (40)

1. Steckelings UM, Rompe F, Kaschina E, Unger T. The evolving story of the RAAS in hypertension, diabetes and CV disease: moving from macrovascular to microvascular targets. Fundam Clin Pharmacol 2009; 23: 693-703.
2. Henriksen EJ. Improvement of insulin sensitivity by antagonism of the renin-angiotensin system. Am J Physiol Regul Integr Comp Physiol 2007; 293: 974-980.
3. Cassis LA, Police SB, Yiannikouris F, Thatcher SE. Local adipose tissue reninangiotensin system. Curr Hypertens Rep 2008; 10: 93-98.
4. Brucher R, Cifuentes M, Acuna MJ, Albala C, Rojas CV. Larger anti-adipogenic effect of angiotensin II on omental preadipose cells of obese humans. Obesity 2007; 15: 1643-1646.
5. Iwai M, Tomono Y, Inaba S, Kanno H, Senba I, Mogi M, Horiuchi M. AT2 receptor deficiency attenuates adipocyte differentiation and decreases adipocyte number in atherosclerotic mice. Am J Hypertens 2009; 22: 784-791.
6. Storka A, Vojtassakova E, Mueller M, Kapiotis S, Haider DG, Jungbauer A, Wolzt M. Angiotensin inhibition stimulates PPARgamma and the release of visfatin. Eur J Clin Invest 2008; 38: 820-826.
7. Adeghate E. Visfatin: structure, function and relation to diabetes mellitus and other dysfunctions. Curr Med Chem 2008; 15: 1851-1862.
8. Rasouli N, Kern PA. Adipocytokines and the metabolic complications of obesity. J Clin Endocrinol Metab 2008; 93(11 Suppl 1): S64-S73.
9. Fogari R, Zoppi A, Ferrari I, Mugellini A, Preti P, Lazzari P, Derosa G. Comparative effects of telmisartan and eprosartan on insulin sensitivity in the treatment of overweight hypertensive patients. Horm Metab Res 2009; 41: 893-898.
10. Derosa G, Fogari E, D'Angelo A, Cicero AF, Salvadeo SA, Ragonesi PD, Ferrari I, Gravina A, Fassi R, Fogari R. Metabolic effects of telmisartan and irbesartan in type 2 diabetic patients with metabolic syndrome treated with rosiglitazone. J Clin Pharm Ther 2007; 32: 261-268. (Pubitemid 46699517)
11. Nakayama S, Watada H, Mita T, Ikeda F, Shimizu T, Uchino H, Fujitani Y, Hirose T, Kawamori R. Comparison of effects of olmesartan and telmisartan on blood pressure and metabolic parameters in Japanese early-stage type-2 diabetics with hypertension. Hypertens Res 2008; 31: 7-13.
12. Bunn HF, Gabbay KH, Gallop PM. The glycosylation of haemoglobin. Relevance to diabetes mellitus. Science 1978; 200: 21-27.
13. European Diabetes Policy Group. A desktop guide to type 2 diabetes mellitus. Diabet Med 1999; 16: 716-730.
14. Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, Mori Y, Ide T, Murakami K, Tsuboyama-Kasaoka N, Ezaki O, Akanuma Y, Gavrilova O, Vinson C, Reitman ML, Kagechika H, Shudo K, Yoda M, Nakano Y, Tobe K, Nagai R, Kimura S, Tomita M, Froguel P, Kadowaki T. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nature Med 2001; 7: 941-946.
15. Yannakoulia M, Yiannakouris N, Bluher S, Matalas AL, Klimis-Zacas D, Mantzoros CS. Body fat mass and macronutrient intake in relation to circulating soluble leptin receptor, free leptin index, adiponectin, and resistin concentrations in healthy humans. J Clin Endocrinol Metabol 2003; 88: 1730-1736.
16. Takebayashi K, Suetsugu M, Wakabayashi S, Aso Y, Inumai T. Retinol binding protein-4 and clinical features of type 2 diabetes patients. J Clin Endocrinol Metab 2007; 92: 2712-2719.
17. Korner A, Garten A, Bluher M, Tauscher R, Kratzsch J, Kiess W. Molecular characteristics of serum visfatin and differential detection by immunoassays. J Clin Endocrinol Metab 2007; 92: 4783-4791.
18. Hida K, Wada J, Eguchi J, Zhang H, Baba M, Seida A, Hashimoto I, Okada T, Yasuhara A, Nakatsuka A, Shikata K, Hourai S, Futami J, Watanabe E, Matsuki Y, Hiramatsu R, Akagi S, Makino H, Kanwar YS. Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity. Proc Natl Acad Sci 2005; 102: 10610-10615.
19. Rifai N, Tracy RP, Ridker PM. Clinical efficacy of an automated high-sensitivity C-reactive protein assay. Clin Chem 1999; 45: 2136-2141.
20. De Fronzo RA, Tobin JA, Andres B. Glucose clamp technique, a method for quantifying insulin secretion and resistance. Am J Physiol 1979; 237: 214-223.
21. Ferrannini E, Buzzigoli G, Bonadonna R, GioricoMA, Oleggini M, Graziadei L, Pedrinelli R, Brandi L, Bevilacqua S. Insulin resistance in essential hypertension. N Engl J Med 1987; 317: 350-357.
22. Winer BJ. Statistical Principles in Experimental Design. 2nd edn. McGraw-Hill, New York, 1971.
23. Segura J, Ruilope LM. Obesity, essential hypertension and renin-angiotensin system. Public Health Nutr 2007; 10: 1151-1155.
24. Sugihara M, Miura S, Takamiya Y, Kiya Y, Arimura T, Iwata A, Kawamura A, Nishikawa H, Uehara Y, Saku K. Safety and efficacy of antihypertensive therapy with add-on angiotensin II type 1 receptor blocker after successful coronary stent implantation. Hypertens Res 2009; 32: 625-630.
25. Derosa G, Maffioli P, Salvadeo SA, Ferrari I, Gravina A, Mereu R, Palumbo I, D'Angelo A, Cicero AF. Candesartan effect on inflammation in hypertension. Hypertens Res 2010; 33: 209-213.
26. Jackson MB, Ahima RS. Neuroendocrine and metabolic effects of adipocyte-derived hormones. Clin Sci 2006; 110: 143-152.
27. Berg AH, Combs TP, Scherer PE. ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism. Trends Endocrinol Metab 2002; 13: 84-89.
28. Berg AH, Combs TP, Du X, Brownlee M, Scherer PE. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 2001; 7: 947-953.
29. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR, Ahima RS, Lazar MA. The hormone resistin links obesity to diabetes. Nature (London) 2001; 409: 307-312.
30. Satoh H, Nguyen MT, Miles PD, Imamura T, Usui I, Olefsky JM. Adenovirus-mediated chronic 'hyper-resistinemia' leads to in vivo insulin resistance in normal rats. J Clin Invest 2004; 114: 224-231.
31. Rangwala SM, Rich AS, Rhoades B, Shapiro JS, Obici S, Rossetti L, Lazar MA. Abnormal glucose homeostasis due to chronic hyperresistinemia. Diabetes 2004; 53: 1937-1941.
32. Reilly MP, Lehrke M, Wolfe M, Rohatgi A, Lazar MA, Rader DJ. Resistin is an inflammatory marker of atherosclerosis in humans. Circulation 2005; 111: 932-939.
33. Cho YM, Youn BS, Lee H, Lee N, Min SS, Kwak SH, Lee HK, Park KS. Plasma retinolbinding protein-4 concentrations are elevated in human subjects with impaired glucose tolerance and type 2 diabetes. Diabetes Care 2006; 29: 2457-2461.
34. Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, Matsuki Y, Murakami M, Ichisaka T, Murakami H, Watanabe E, Takagi T, Akiyoshi M, Ohtsubo T, Kihara S, Yamashita S, Makishima M, Funahashi T, Yamanaka S, Hiramatsu R, Matsuzawa Y, Shimomura I. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 2005; 307: 426-430. (Pubitemid 40139988)
35. Hug C, Lodish HF. Visfatin: a new adipokine. Science 2005; 307: 366-367.
36. Rifai N, Tracy RP, Ridker PM. Clinical efficacy of an automated high-sensitivity C-reactive protein assay. Clin Chem 1999; 45: 2136-2141.
37. Furuya R, Odamaki M, Kumagai H, Hishida A. Impact of angiotensin II receptor blocker on plasma levels of adiponectin and advanced oxidation protein products in peritoneal dialysis patients. Blood Purif 2006; 24: 445-450.
38. Furuhashi M, Ura N, Higashiura K, Murakami H, Tanaka M, Moniwa N, Yoshida D, Shimamoto K. Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension 2003; 42: 76-81.
39. De Vinuesa SG, Goicoechea M, Kanter J, Puerta M, Cachofeiro V, Lahera V, Gómez-Campderá F, Luñ o J. Insulin resistance, inflammatory biomarkers, and adipokines in patients with chronic kidney disease: effects of angiotensin II blockade. J Am Soc Nephrol 2006; 17 (12 Suppl 3): S206-S212.
40. Derosa G, Cicero AF, D'Angelo A, Ragonesi PD, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo SA, Ferrari I, Gravina A, Fogari R. Telmisartan and irbesartan therapy in type 2 diabetic patients treated with rosiglitazone: effects on insulin-resistance, leptin and tumor necrosis factor-alpha. Hypertens Res 2006; 29: 849-856.